Sebastian Lewandowski
About me
2018 - ongoing - Team Leader at the Department of Clinical Neuroscience and Center for Molecular Medicine
2008 - 2018 - Postdoc. Ulf Eriksson group, Karolinska Institutet
2005 - PhD degree. Nencki Institute of Experimental Biology, Warsaw, Poland
1997 - MSc degree. University of Gdansk, Poland
Research
Our team studies cellular mechanisms of cerebrovascular injury mechanisms in ALS neurodegeneration to find novel clinical biomarkers and therapeutic solutions.
Publication highlight:
Månberg A. et al. Nature Medicine, April 2021
"Altered perivascular fibroblast activity precedes ALS disease onset".
Nature Medicine News and Views, April 2021
"Is presymptomatic ALS perivascular?"
Karolinska Institute Press release.
"New type of cell contributes to increased understanding of ALS"
Our web resource for cell-specific gene expression in ALS:
https://alscellatlas.org/
We look at how blood vessel dysfunction and vascular remodelling lead to
increased severity of Amyotrophic Lateral Sclerosis (ALS) and FTD using
bioinformatics, in-vivo rodent models and clinical samples. We collaborate
with the leading neurology centres in Europe and US including UZ Leuven in
Belgium, Univ. Utrecht in Holland, Ulm Univ. in Germany and UCSD in San
Diego. Our results lead to novel off-label drug applications to therapy and
biomarkers in neurodegeneration including ALS, stroke and multiple sclerosis.
We offer Master student, PhD and Postdoc positions to highly motivated and
enthusiastic researchers. For details, send an email to sebastian.lewandowski@ki.se
Teaching
2020 - ongoing - PhD course director "The Vascular Brain"
2008 - ongoing - Lecturer and group discussion leader in the Biomedicine program
2018 - ongoing - MSc student supervision
Articles
- Article: JOURNAL OF CLINICAL INVESTIGATION. 2025;:e171077
- Journal article: EBIOMEDICINE. 2024;110:105470
- Journal article: CEREBRAL CIRCULATION, COGNITION AND BEHAVIOR. 2024;6:100049
- Article: FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY. 2023;11:1169962
- Article: NEUROTHERAPEUTICS. 2021;18(3):1963-1979
- Article: NATURE MEDICINE. 2021;27(4):640-646
- Journal article: DISEASE MODELS & MECHANISMS. 2020;13(5):dmm045310
- Article: DISEASE MODELS & MECHANISMS. 2019;12(8):dmm040238
- Article: NEUROBIOLOGY OF DISEASE. 2018;119:26-40
- Article: NEUROPHARMACOLOGY. 2018;133:503-511
- Article: ACTA NEUROPATHOLOGICA. 2016;131(3):453-464
- Article: PLOS ONE. 2012;7(6):e38760
- Article: CARCINOGENESIS. 2009;30(4):575-579
- Article: ONCOGENE. 2008;27(7):1019-1032
- Article: ONCOGENE. 2005;24(30):4789-4798
- Article: INTERNATIONAL JOURNAL OF CANCER. 2004;110(6):783-787
- Article: CANCER LETTERS. 2001;164(2):143-148
All other publications
- Review: FRONTIERS IN VETERINARY SCIENCE. 2023;10:1135282
- Review: FRONTIERS IN NEUROLOGY. 2022;13:947347
- Corrigendum: NATURE MEDICINE. 2021;27(7):1308
- Conference publication: INTERNATIONAL JOURNAL OF STROKE. 2020;15(1_SUPPL):624-625
- Review: PHARMACOLOGY & THERAPEUTICS. 2016;167:108-119
- Editorial comment: EXPERIMENTAL NEUROLOGY. 2014;257:182-185
- Book chapter: HORMONAL CARCINOGENESIS IV. 2005;p. 314-320
- Review: FEBS LETTERS. 2002;524(1-3):1-5
Grants
- Karolinska Institutet1 January 2024 - 1 January 2028
- Swedish Brain Foundation1 January 2022 - 1 January 2024
- Swedish Research Council1 January 2022 - 31 December 2024
- Molecular phenotyping of brain metabolism in asymptomatic ALS/FTD patientsKarolinska Institutet1 January 2022 - 1 January 2024
- Frick Foundation1 January 2021 - 1 January 2022